Usage: TYSABRI treats relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing-remitting, and active secondary progressive disease) in adults, and induces and maintains remission in adults with moderately to severely active Crohn's disease unresponsive to conventional therapies or TNF-α inhibitors.